Wedbush Downgrades iTeos Therapeutics (NASDAQ:ITOS) to Neutral
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, MarketBeat Ratings reports. They presently have a $12.00 price objective on the stock, up from their previous price objective of $10.00. Wedbush’s target price would suggest a […]
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, MarketBeat Ratings reports. They presently have a $12.00 price objective on the stock, up from their previous price objective of $10.00. Wedbush’s target price would suggest a […]
